Insperity Projects 2026 Earnings Rebound After Tough 2025
Insperity ((NSP)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Insperity’s latest earnings call struck a cautious but hopeful tone as management paired stark 2025 profit declines with an ambitious recovery plan for 2026. Executives acknowledged heavy margin pressure from healthcare costs and restructuring, yet emphasized cost cuts, pricing actions and the HRScale rollout as key levers for a multi‑year rebound in earnings power.
2026 Profitability Outlook Signals Strong Earnings Rebound
Management projected 2026 adjusted EBITDA between $170 million and $230 million, implying a jump of roughly 30% to 76% versus 2025. Adjusted EPS is expected to climb to a range of $1.69 to $2.72, a 64% to 164% surge that, if achieved, would mark a sharp recovery from this year’s earnings slump.
Q4 Results Negative But Largely In Line With Forecasts
Fourth quarter 2025 performance remained under pressure, with adjusted EPS at negative $0.60 and adjusted EBITDA at negative $13 million. Excluding $2.8 million of sales office consolidation expense, adjusted EPS would have been negative $0.54 and adjusted EBITDA negative $11 million, which management said landed around the midpoint of prior guidance.
Worksite Employee Growth and Exceptional Retention Metrics
Insperity reported average paid worksite employees of 312,377 in Q4, up 1.1% year over year, showing that the client base is still edging higher. New client worksite employees rose 6% and monthly client retention hovered near 99%, pointing to sticky relationships even as full‑year retention sat in the low‑80% range.
Expense Discipline and Margin-Focused Fall Campaign
Operating expenses fell 6% versus the prior‑year quarter, reflecting tightening across the organization. A fall sales and retention campaign prioritized margin recovery, and management highlighted early signs that better pricing and more selective client onboarding are starting to lift gross profit drivers.
HRScale: Heavy Investment Aimed at Future Growth
The company poured $59 million into its HRScale platform in 2025, with $48 million expensed and $11 million capitalized, and Q4 alone saw $15 million of investment. Beta clients are preparing to go live, and Insperity expects 6,000 to 8,000 paid worksite employees on HRScale by the end of 2026, targeting a larger addressable market and improved long‑term revenue and retention.
Capital Returns and Strengthened Liquidity Position
Shareholders continued to see cash returned, with $90 million paid in dividends over 2025 and 232,000 shares repurchased for $19 million. Liquidity was bolstered as the credit facility was amended and extended, lifting capacity from $650 million to $750 million and leaving $380 million of borrowing headroom at year‑end.
2025 Profitability Hit Highlights Near-Term Strain
Full‑year 2025 adjusted EBITDA dropped 51% to $131 million, while adjusted EPS fell 71% to $1.03, underscoring the severity of the margin squeeze. The negative Q4 adjusted EPS and EBITDA, alongside elevated healthcare costs, reinforced that the business is currently in a reset phase rather than a growth phase for earnings.
Rising Healthcare Claims Compress Margins Despite Pricing Actions
An industry‑wide spike in healthcare claim costs materially pressured gross profit per worksite employee, which was $183 per month in Q4. Management expects these elevated claims to persist into 2026 and is pushing pricing increases “in the teens” plus plan design changes and a UnitedHealthcare renegotiation that together should trim costs by about 2%.
Lower Starting Headcount Dampens 2026 Growth Prospects
Year‑end transition decisions and softer client net hiring left the company with several thousand fewer paid worksite employees than planned. As a result, 2026 guidance calls for average worksite employees to range from down 1.5% to up 1.5% versus 2025, with Q1 projected at 303,000 to 305,000, a modest year‑over‑year decline.
Margin Recovery Strategy Weighs On Near-Term Sales
The push for better pricing and stricter client selection has had a cost: new booked sales in November and December came in below expectations. Management also saw an uptick in company‑initiated nonrenewals, actions that should support unit economics over time but are currently a drag on headline growth.
Restructuring, Cash Position and Interest Income Headwinds
Insperity is realigning its workforce, cutting about 4% of non‑sales staff and taking an estimated $9 million restructuring charge, which will be excluded from adjusted metrics. Adjusted cash stood at $57 million at quarter‑end, and the company flagged roughly $7 million less interest income in 2026, noting it may tap its expanded credit facility if conditions warrant.
Guidance Points to Recovery in 2026 Amid Ongoing Pressures
Management’s 2026 guidance assumes average worksite employee counts roughly flat, offset by about $20 million of operating expense savings and lower HRScale operating spend, with CapEx of $40 million to $45 million and an adjusted tax rate near 34%. Within that framework, the company targets adjusted EBITDA of $170 million to $230 million and adjusted EPS of $1.69 to $2.72, with Q1 expected to deliver $81 million to $111 million in adjusted EBITDA and $1.03 to $1.50 in adjusted EPS.
Insperity’s call framed 2025 as a difficult transition year marked by compressed margins, restructuring and subdued growth, but laid out a detailed plan for a profitability rebound in 2026. For investors, the story now hinges on whether pricing, cost actions and HRScale adoption can offset healthcare pressures and soft volumes, turning today’s reset into tomorrow’s earnings recovery.
